If bacteria aren’t the whole story of the tumor microenvironment, what crucial signals are being missed from fungi that quietly occupy the same space yet account for only a sliver of the sequencing reads but a disproportionate share of immune cues and clinical outcomes? That challenge has gained
Could a single seed pull double duty against inflammation, oxidative stress, microbes, and metabolic drift without the side-effect ledger that shadows many prescriptions, and could it do so in a way that complements rather than competes with standard care? That is the provocation driving a surge of
In a world where a stroke strikes someone every 40 seconds, the fear of a second, potentially fatal event looms large for millions of survivors, creating an urgent need for better solutions. Picture a patient, just recovered from an initial stroke, grappling with the uncertainty of whether their
I'm thrilled to sit down with Dr. Ivan Kairatov, a renowned expert in pediatric medicine with a focus on liver transplantation and patient-reported outcomes. With years of experience in research and innovation, Dr. Kairatov has been at the forefront of shifting how we understand children's
What happens when a beacon of hope for millions battling multiple sclerosis (MS) dims in a single clinical trial? In a field where breakthroughs are rare and desperately needed, Contineum Therapeutics, a San Diego-based biotech firm, has hit a significant roadblock with their lead drug, PIPE-307,
In the high-stakes world of intensive care units (ICUs), severe community-acquired pneumonia (CAP) stands as a formidable adversary, often demanding prolonged hospital stays and extensive resources like ventilatory support, especially among older adults. This condition, contracted outside hospital
